Alcista
$2.27
Precio del escenario
$0.390
-0.080 (-20.61%)Al cierre
SelectQuote, Inc. provides a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. The Company has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products. SelectQuote Healthcare Services comprises SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with healthcare services that fit each member's healthcare needs. SelectQuote’s Auto & Home division primarily sells non-commercial auto and home, property and casualty insurance products. SelectQuote’s Life division sells term life, final expenses, and other ancillary products. SelectRx is a Patient-Centered Pharmacy Home (PCPH) accredited pharmacy.
SelectQuote Inc (SLQT) appears to be a good buy right now due to its recent price momentum and favorable valuation metrics. The current price is $0.402, which is significantly below its 52-week high of $2.17, indicating potential for recovery. The stock has shown a 5-day change of +22.90%, reflecting strong short-term performance. Additionally, the forward P/E ratio is 66.67, suggesting that while the stock is expensive based on earnings, it is trading at a low price-to-sales ratio of 0.0395, indicating it may be undervalued relative to its sales. However, the main risk is the negative earnings per share (EPS) estimate of -0.26 for the upcoming quarter, which could lead to further volatility.
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.

SelectQuote to Release Q1 2027 Financial Results on November 4, 2026

SelectQuote Reports Q4 FY2026 Earnings Highlights

SelectQuote to Release Q4 and Full Year 2026 Financial Results

SelectQuote Faces Shareholder Lawsuit Investigation

SelectQuote Executives Allegedly Breached Fiduciary Duties
SelectQuote, Inc. provides a technology-enabled, direct-to-consumer (DTC) distribution and engagement platform for selling insurance policies and healthcare services. The Company has four core business lines: SelectQuote Senior, SelectQuote Healthcare Services, SelectQuote Life, and SelectQuote Auto and Home. SelectQuote’s Senior division sells Medicare Advantage, Medicare Supplement, Medicare Part D, and other ancillary senior health insurance related products. SelectQuote Healthcare Services comprises SelectRx Pharmacy, a specialized medication management pharmacy, and Population Health which proactively connects its members with healthcare services that fit each member's healthcare needs. SelectQuote’s Auto & Home division primarily sells non-commercial auto and home, property and casualty insurance products. SelectQuote’s Life division sells term life, final expenses, and other ancillary products. SelectRx is a Patient-Centered Pharmacy Home (PCPH) accredited pharmacy. It operates in the Financials sector (INSURANCE AGENTS, BROKERS & SERVICE industry).
SelectQuote Inc (SLQT) appears to be a good buy right now due to its recent price momentum and favorable valuation metrics. The current price is $0.402, which is significantly below its 52-week high of $2.17, indicating potential for recovery. The stock has shown a 5-day change of +22.90%, reflecting strong short-term performance. Additionally, the forward P/E ratio is 66.67, suggesting that while the stock is expensive based on earnings, it is trading at a low price-to-sales ratio of 0.0395, indicating it may be undervalued relative to its sales. However, the main risk is the negative earnings per share (EPS) estimate of -0.26 for the upcoming quarter, which could lead to further volatility.
Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.